Nurix Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 12, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Market Cap	2,727	1,800	1,678	303	584	1,287
Market Cap Growth	262.56%	7.30%	453.58%	-48.15%	-54.60%	-22.29%
Enterprise Value	2,342	1,263	1,096	45.74	287.29	1,005
Last Close Price	26.28	17.68	22.11	6.22	12.39	28.82
PS Ratio	73.28	21.43	30.75	3.94	15.13	43.27
PB Ratio	6.69	3.34	3.18	1.51	1.92	3.76
P/TBV Ratio	6.53	2.84	2.82	1.69	1.98	3.61
EV/Sales Ratio	62.80	15.04	20.10	0.59	7.44	33.77
Debt / Equity Ratio	0.14	0.10	0.04	0.12	0.02	0.03
Net Debt / Equity Ratio	-0.96	-1.00	-1.10	-1.28	-0.98	-0.83
Net Debt / EBITDA Ratio	1.10	2.01	2.96	1.82	1.72	2.53
Net Debt / FCF Ratio	6.41	2.04	3.19	2.88	1.73	3.14
Asset Turnover	0.06	0.12	0.11	0.20	0.09	0.07
Quick Ratio	6.16	6.86	6.36	3.31	4.38	4.56
Current Ratio	6.34	7.02	6.46	3.40	4.51	4.70
Return on Equity (ROE)	-72.52%	-49.63%	-53.22%	-57.10%	-55.84%	-37.05%
Return on Assets (ROA)	-58.98%	-42.21%	-41.63%	-40.15%	-41.16%	-27.03%
Return on Invested Capital (ROIC)	-4495.14%	-	-	-	-556.02%	-343.38%
Return on Capital Employed (ROCE)	-67.82%	-48.62%	-50.59%	-50.45%	-48.60%	-30.93%
Buyback Yield / Dilution	-25.67%	-29.12%	-23.52%	-11.79%	-13.32%	-173.68%
Total Shareholder Return	-25.67%	-29.12%	-23.52%	-11.79%	-13.32%	-173.68%

SEC Filings: 10-K · 10-Q